ABBV vs HALO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.
HALO presents a stark contrast between operational efficiency and valuation sanity. While the Piotroski F-Score of 4/9 indicates stable financial health, the stock trades at a massive premium to its Graham Number ($4.88) and Intrinsic Value ($17.92). Despite exceptional operating margins (56.31%) and strong revenue growth (51.6%), the recent collapse in EPS (-114% Q/Q) and aggressive insider selling by the CEO and COO create significant headwinds that offset the bullish analyst consensus.
Compare Another Pair
Related Comparisons
ABBV vs HALO: Head-to-Head Comparison
This page compares AbbVie Inc. (ABBV) and Halozyme Therapeutics, Inc. (HALO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.